CritiTech Announces Coating Agreement with Major Device Company

August 22, 2005

Lawrence, Kan. - CritiTech announced today that it signed an agreement with a major international device company to develop improved processes for the coating of implantable devices such as cardiac stents. CritiTech has numerous patents using supercritical fluid technology for the production of nano/micro particle pharmaceutical compounds and for the coating of substrates.

“This demonstrates the progress that our company has made in developing our coating technology. Through an additional agreement with an international pharmaceutical company, CritiTech intends to develop a variety of proprietary methods for coating small particle compounds,” said Crititech CEO and President Sam Campbell.

CritiTech provides critical drug delivery and development technology for the pharmaceutical industry. CritiTech produces fine-particle pharmaceuticals including nanoparticle pharmaceuticals using patented technologies developed at the University of Kansas. The processes use compressed carbon dioxide as the processing medium to produce relatively residue-free and uniform drug microparticles and coatings.

The pharmaceutical industry has exhibited substantial interest in processes that produce improved formulations using nanoparticulate drugs in order to extend the patent life of an existing drug or to enable the delivery of a poorly soluble compound. CritiTech has also successfully used its proprietary technology to coat medicinal agents either on small particle drugs for improved drug delivery or as a thin film on implantable medical devices such as cardiac stents. The Nanotax™ ovarian cancer drug is the first drug to be announced under the company’s drug development program.